Coverage / CTXR / Trade Card

CTXR

Citius Pharmaceuticals Inc

OPPORTUNISTIC BUY Analysis generated 2026-10-04 Market data as of 2026-11-12 Market data 3 days old USD 0.53 Healthcare - BiotechnologyAWAIT ENTRY
ACTIONABLEMethodology gates passed
59

Position levels

Currenttoday
USD 0.53
Buy <=wait / entry
USD 0.43
Trim >=take some off
USD 0.70
Thesis breakA material adverse event affecting LYMPHIR commercialisation such as a regulator...
-

Scenario-weighted conviction

ProbabilityScoreContribution
Bull case25%100 / 10025.0
Base case50%62 / 10031.0
Bear case25%10 / 1002.5
Weighted conviction59 / 100 - OPPORTUNISTIC BUY

Top risks

  • Launch of LYMPHIR with strong early adoption and broad reimbursement
  • Completion of merger of subsidiary with TenX Keane to form Citius Oncology, Inc.
  • $5 million registered direct offering priced at-the-market with accompanying warrants
Read full report →

Research is for informational purposes only. Not financial advice. All analysis reflects the date of publication.

\n